Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 41 entries
Sorted by: Best Match Show Resources per page
What Is Cystic Fibrosis?.

JAMA

Endres TM, Konstan MW.
PMID: 35015036
JAMA. 2022 Jan 11;327(2):191. doi: 10.1001/jama.2021.23280.

No abstract available.

Cite
Endres TM, Konstan MW. What Is Cystic Fibrosis?. JAMA. 2022;327(2):191doi: 10.1001/jama.2021.23280.
Endres, T. M., & Konstan, M. W. (2022). What Is Cystic Fibrosis?. JAMA, 327(2), 191. https://doi.org/10.1001/jama.2021.23280
Endres, Tori M, and Konstan, Michael W. "What Is Cystic Fibrosis?." JAMA vol. 327,2 (2022): 191. doi: https://doi.org/10.1001/jama.2021.23280
Endres TM, Konstan MW. What Is Cystic Fibrosis?. JAMA. 2022 Jan 11;327(2):191. doi: 10.1001/jama.2021.23280. PMID: 35015036.
Copy Download .nbib Format: NLM
Efficacy and Safety of a New Formulation of Pancrelipase (Ultrase MT20) in the Treatment of Malabsorption in Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

Gastroenterology research and practice

Konstan MW, Liou TG, Strausbaugh SD, Ahrens R, Kanga JF, Graff GR, Moffett K, Millard SL, Nasr SZ, Siméon E, Spénard J, Grondin J.
PMID: 21197074
Gastroenterol Res Pract. 2010;2010:898193. doi: 10.1155/2010/898193. Epub 2010 Dec 08.

Background. Pancreatic enzyme replacement therapy is the standard of care for treatment of malabsorption in patients with cystic fibrosis (CF) and exocrine pancreatic insufficiency (PI). Aim. To evaluate efficacy and safety of a new formulation of pancrelipase (Ultrase MT20)...

Cite
Konstan MW, Liou TG, Strausbaugh SD, et al. Efficacy and Safety of a New Formulation of Pancrelipase (Ultrase MT20) in the Treatment of Malabsorption in Exocrine Pancreatic Insufficiency in Cystic Fibrosis. Gastroenterol Res Pract. 2010;2010:898193doi: 10.1155/2010/898193.
Konstan, M. W., Liou, T. G., Strausbaugh, S. D., Ahrens, R., Kanga, J. F., Graff, G. R., Moffett, K., Millard, S. L., Nasr, S. Z., Siméon, E., Spénard, J., & Grondin, J. (2010). Efficacy and Safety of a New Formulation of Pancrelipase (Ultrase MT20) in the Treatment of Malabsorption in Exocrine Pancreatic Insufficiency in Cystic Fibrosis. Gastroenterology research and practice, 2010898193. https://doi.org/10.1155/2010/898193
Konstan, Michael W, et al. "Efficacy and Safety of a New Formulation of Pancrelipase (Ultrase MT20) in the Treatment of Malabsorption in Exocrine Pancreatic Insufficiency in Cystic Fibrosis." Gastroenterology research and practice vol. 2010 (2010): 898193. doi: https://doi.org/10.1155/2010/898193
Konstan MW, Liou TG, Strausbaugh SD, Ahrens R, Kanga JF, Graff GR, Moffett K, Millard SL, Nasr SZ, Siméon E, Spénard J, Grondin J. Efficacy and Safety of a New Formulation of Pancrelipase (Ultrase MT20) in the Treatment of Malabsorption in Exocrine Pancreatic Insufficiency in Cystic Fibrosis. Gastroenterol Res Pract. 2010;2010:898193. doi: 10.1155/2010/898193. Epub 2010 Dec 08. PMID: 21197074; PMCID: PMC3004382.
Copy Download .nbib Format: NLM
Heart Failure Costs, Minority Populations, and Outcomes: Targeting Health Status, Not Utilization, to Bend the Cost-Effectiveness Curve.

JACC. Heart failure

Konstam MA.
PMID: 29655823
JACC Heart Fail. 2018 May;6(5):398-400. doi: 10.1016/j.jchf.2018.02.005. Epub 2018 Apr 11.

No abstract available.

Cite
Konstam MA. Heart Failure Costs, Minority Populations, and Outcomes: Targeting Health Status, Not Utilization, to Bend the Cost-Effectiveness Curve. JACC Heart Fail. 2018;6(5):398-400doi: 10.1016/j.jchf.2018.02.005.
Konstam, M. A. (2018). Heart Failure Costs, Minority Populations, and Outcomes: Targeting Health Status, Not Utilization, to Bend the Cost-Effectiveness Curve. JACC. Heart failure, 6(5), 398-400. https://doi.org/10.1016/j.jchf.2018.02.005
Konstam, Marvin A. "Heart Failure Costs, Minority Populations, and Outcomes: Targeting Health Status, Not Utilization, to Bend the Cost-Effectiveness Curve." JACC. Heart failure vol. 6,5 (2018): 398-400. doi: https://doi.org/10.1016/j.jchf.2018.02.005
Konstam MA. Heart Failure Costs, Minority Populations, and Outcomes: Targeting Health Status, Not Utilization, to Bend the Cost-Effectiveness Curve. JACC Heart Fail. 2018 May;6(5):398-400. doi: 10.1016/j.jchf.2018.02.005. Epub 2018 Apr 11. PMID: 29655823.
Copy Download .nbib Format: NLM
Radiology diagnostic exchange agents: clinical term identification and validation.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science

Shores KB, Konstan JA, Riedl JT, Taylor AJ, Steinberger DJ, Adam TJ.
PMID: 24303275
AMIA Jt Summits Transl Sci Proc. 2013 Mar 18;2013:244-8. eCollection 2013.

Diagnostic radiology is one of the key areas of clinical diagnosis on which much of the health care system is built. Along with pathology, radiology has a unique role in providing diagnostic information for prognosis, treatment, and management of...

Cite
Shores KB, Konstan JA, Riedl JT, et al. Radiology diagnostic exchange agents: clinical term identification and validation. AMIA Jt Summits Transl Sci Proc. 2013;2013:244-8
Shores, K. B., Konstan, J. A., Riedl, J. T., Taylor, A. J., Steinberger, D. J., & Adam, T. J. (2013). Radiology diagnostic exchange agents: clinical term identification and validation. AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science, 2013244-8.
Shores, Kenneth B, et al. "Radiology diagnostic exchange agents: clinical term identification and validation." AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science vol. 2013 (2013): 244-8.
Shores KB, Konstan JA, Riedl JT, Taylor AJ, Steinberger DJ, Adam TJ. Radiology diagnostic exchange agents: clinical term identification and validation. AMIA Jt Summits Transl Sci Proc. 2013 Mar 18;2013:244-8. eCollection 2013. PMID: 24303275; PMCID: PMC3845772.
Copy Download .nbib Format: NLM
Nesiritide ASCENDs the ranks of unproven treatments for acute heart failure.

American journal of kidney diseases : the official journal of the National Kidney Foundation

Kociol RD, Konstam MA.
PMID: 22305860
Am J Kidney Dis. 2012 Jul;60(1):8-11. doi: 10.1053/j.ajkd.2011.12.012. Epub 2012 Feb 02.

No abstract available.

Cite
Kociol RD, Konstam MA. Nesiritide ASCENDs the ranks of unproven treatments for acute heart failure. Am J Kidney Dis. 2012;60(1):8-11doi: 10.1053/j.ajkd.2011.12.012.
Kociol, R. D., & Konstam, M. A. (2012). Nesiritide ASCENDs the ranks of unproven treatments for acute heart failure. American journal of kidney diseases : the official journal of the National Kidney Foundation, 60(1), 8-11. https://doi.org/10.1053/j.ajkd.2011.12.012
Kociol, Robb D, and Konstam, Marvin A. "Nesiritide ASCENDs the ranks of unproven treatments for acute heart failure." American journal of kidney diseases : the official journal of the National Kidney Foundation vol. 60,1 (2012): 8-11. doi: https://doi.org/10.1053/j.ajkd.2011.12.012
Kociol RD, Konstam MA. Nesiritide ASCENDs the ranks of unproven treatments for acute heart failure. Am J Kidney Dis. 2012 Jul;60(1):8-11. doi: 10.1053/j.ajkd.2011.12.012. Epub 2012 Feb 02. PMID: 22305860.
Copy Download .nbib Format: NLM
Influence of Patient Characteristics and Psychological Needs on Diabetes Mobile App Usability in Adults With Type 1 or Type 2 Diabetes: Crossover Randomized Trial.

JMIR diabetes

Fu HN, Adam TJ, Konstan JA, Wolfson JA, Clancy TR, Wyman JF.
PMID: 31038468
JMIR Diabetes. 2019 Apr 30;4(2):e11462. doi: 10.2196/11462.

BACKGROUND: More than 1100 diabetes mobile apps are available, but app usage by patients is low. App usability may be influenced by patient factors such as age, sex, and psychological needs.OBJECTIVE: Guided by Self-Determination Theory, the purposes of this...

Cite
Fu HN, Adam TJ, Konstan JA, et al. Influence of Patient Characteristics and Psychological Needs on Diabetes Mobile App Usability in Adults With Type 1 or Type 2 Diabetes: Crossover Randomized Trial. JMIR Diabetes. 2019;4(2):e11462doi: 10.2196/11462.
Fu, H. N., Adam, T. J., Konstan, J. A., Wolfson, J. A., Clancy, T. R., & Wyman, J. F. (2019). Influence of Patient Characteristics and Psychological Needs on Diabetes Mobile App Usability in Adults With Type 1 or Type 2 Diabetes: Crossover Randomized Trial. JMIR diabetes, 4(2), e11462. https://doi.org/10.2196/11462
Fu, Helen Nc, et al. "Influence of Patient Characteristics and Psychological Needs on Diabetes Mobile App Usability in Adults With Type 1 or Type 2 Diabetes: Crossover Randomized Trial." JMIR diabetes vol. 4,2 (2019): e11462. doi: https://doi.org/10.2196/11462
Fu HN, Adam TJ, Konstan JA, Wolfson JA, Clancy TR, Wyman JF. Influence of Patient Characteristics and Psychological Needs on Diabetes Mobile App Usability in Adults With Type 1 or Type 2 Diabetes: Crossover Randomized Trial. JMIR Diabetes. 2019 Apr 30;4(2):e11462. doi: 10.2196/11462. PMID: 31038468; PMCID: PMC6660121.
Copy Download .nbib Format: NLM
Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

VanDevanter DR, Hamblett NM, Simon N, McIntosh J, Konstan MW.
PMID: 32682670
J Cyst Fibros. 2021 Jan;20(1):39-45. doi: 10.1016/j.jcf.2020.07.008. Epub 2020 Jul 15.

BACKGROUND: Cystic fibrosis (CF) pulmonary exacerbations can be serious respiratory events and reduction in exacerbation rate or risk are important efficacy endpoints for CF therapeutic trials. Variability in exacerbation diagnoses and treatment have led drug developers to employ "objective"...

Cite
VanDevanter DR, Hamblett NM, Simon N, et al. Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials. J Cyst Fibros. 2020;20(1):39-45doi: 10.1016/j.jcf.2020.07.008.
VanDevanter, D. R., Hamblett, N. M., Simon, N., McIntosh, J., & Konstan, M. W. (2021). Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 20(1), 39-45. https://doi.org/10.1016/j.jcf.2020.07.008
VanDevanter, Donald R, et al. "Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials." Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society vol. 20,1 (2021): 39-45. doi: https://doi.org/10.1016/j.jcf.2020.07.008
VanDevanter DR, Hamblett NM, Simon N, McIntosh J, Konstan MW. Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials. J Cyst Fibros. 2021 Jan;20(1):39-45. doi: 10.1016/j.jcf.2020.07.008. Epub 2020 Jul 15. PMID: 32682670; PMCID: PMC7362840.
Copy Download .nbib Format: NLM
Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States.

Pulmonary therapy

Thorat T, McGarry LJ, Jariwala-Parikh K, Limone B, Bonafede M, Chandarana K, Konstan MW.
PMID: 33913076
Pulm Ther. 2021 Jun;7(1):281-293. doi: 10.1007/s41030-021-00154-9. Epub 2021 Apr 28.

INTRODUCTION: Ivacaftor was first approved in 2012 for the treatment of a select population of individuals with cystic fibrosis (CF), a rare, life-shortening genetic disease. Reductions in healthcare resource utilization (HCRU) associated with ivacaftor have been observed during limited...

Cite
Thorat T, McGarry LJ, Jariwala-Parikh K, et al. Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States. Pulm Ther. 2021;7(1):281-293doi: 10.1007/s41030-021-00154-9.
Thorat, T., McGarry, L. J., Jariwala-Parikh, K., Limone, B., Bonafede, M., Chandarana, K., & Konstan, M. W. (2021). Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States. Pulmonary therapy, 7(1), 281-293. https://doi.org/10.1007/s41030-021-00154-9
Thorat, Teja, et al. "Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States." Pulmonary therapy vol. 7,1 (2021): 281-293. doi: https://doi.org/10.1007/s41030-021-00154-9
Thorat T, McGarry LJ, Jariwala-Parikh K, Limone B, Bonafede M, Chandarana K, Konstan MW. Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States. Pulm Ther. 2021 Jun;7(1):281-293. doi: 10.1007/s41030-021-00154-9. Epub 2021 Apr 28. PMID: 33913076; PMCID: PMC8137794.
Copy Download .nbib Format: NLM
Rates of Reversal of Volume Overload in Hospitalized Acute Heart Failure: Association With Long-term Kidney Function.

American journal of kidney diseases : the official journal of the National Kidney Foundation

McCallum W, Tighiouart H, Testani JM, Griffin M, Konstam MA, Udelson JE, Sarnak MJ.
PMID: 34843844
Am J Kidney Dis. 2021 Nov 26; doi: 10.1053/j.ajkd.2021.09.026. Epub 2021 Nov 26.

RATIONALE AND OBJECTIVE: Achievement of decongestion in acute heart failure (AHF) is associated with improved survival and cardiovascular outcomes, but can be associated with acute declines in estimated glomerular filtration rate (eGFR). We sought to examine whether rate of...

Cite
McCallum W, Tighiouart H, Testani JM, et al. Rates of Reversal of Volume Overload in Hospitalized Acute Heart Failure: Association With Long-term Kidney Function. Am J Kidney Dis. 2021;doi: 10.1053/j.ajkd.2021.09.026.
McCallum, W., Tighiouart, H., Testani, J. M., Griffin, M., Konstam, M. A., Udelson, J. E., & Sarnak, M. J. (2021). Rates of Reversal of Volume Overload in Hospitalized Acute Heart Failure: Association With Long-term Kidney Function. American journal of kidney diseases : the official journal of the National Kidney Foundation, . https://doi.org/10.1053/j.ajkd.2021.09.026
McCallum, Wendy, et al. "Rates of Reversal of Volume Overload in Hospitalized Acute Heart Failure: Association With Long-term Kidney Function." American journal of kidney diseases : the official journal of the National Kidney Foundation vol. (2021). doi: https://doi.org/10.1053/j.ajkd.2021.09.026
McCallum W, Tighiouart H, Testani JM, Griffin M, Konstam MA, Udelson JE, Sarnak MJ. Rates of Reversal of Volume Overload in Hospitalized Acute Heart Failure: Association With Long-term Kidney Function. Am J Kidney Dis. 2021 Nov 26; doi: 10.1053/j.ajkd.2021.09.026. Epub 2021 Nov 26. PMID: 34843844.
Copy Download .nbib Format: NLM
Comment--Val-HeFT and angiotensin-receptor blockers in perspective: A tale of the blind man and the elephant.

Journal of cardiac failure

Konstam MA.
PMID: 12016625
J Card Fail. 2002 Apr;8(2):56-8. doi: 10.1054/jcaf.2002.32950.

BACKGROUND: The role of angiotensin-receptor blockers (ARBs) in the therapy of chronic heart failure (CHF) has not been clarified. There are no large placebo-controlled trials with these agents. The second Evaluation of Losartan in the Elderly trial (ELITE-II) compared...

Cite
Konstam MA. Comment--Val-HeFT and angiotensin-receptor blockers in perspective: A tale of the blind man and the elephant. J Card Fail. 2002;8(2):56-8doi: 10.1054/jcaf.2002.32950.
Konstam, M. A. (2002). Comment--Val-HeFT and angiotensin-receptor blockers in perspective: A tale of the blind man and the elephant. Journal of cardiac failure, 8(2), 56-8. https://doi.org/10.1054/jcaf.2002.32950
Konstam, Marvin A. "Comment--Val-HeFT and angiotensin-receptor blockers in perspective: A tale of the blind man and the elephant." Journal of cardiac failure vol. 8,2 (2002): 56-8. doi: https://doi.org/10.1054/jcaf.2002.32950
Konstam MA. Comment--Val-HeFT and angiotensin-receptor blockers in perspective: A tale of the blind man and the elephant. J Card Fail. 2002 Apr;8(2):56-8. doi: 10.1054/jcaf.2002.32950. PMID: 12016625.
Copy Download .nbib Format: NLM
Coefficients of fat and nitrogen absorption in healthy subjects and individuals with cystic fibrosis.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG

Borowitz D, Konstan MW, O'Rourke A, Cohen M, Hendeles L, Murray FT.
PMID: 23055842
J Pediatr Pharmacol Ther. 2007 Jan;12(1):47-52. doi: 10.5863/1551-6776-12.1.47.

BACKGROUND: We sought to compare the differences of coefficient of fat absorption (CFA) and coefficient of nitrogen absorption (CNA) in healthy individuals and those with cystic fibrosis (CF) and to study the precision of CFA and CNA.METHODS: Sixteen healthy...

Cite
Borowitz D, Konstan MW, O'Rourke A, et al. Coefficients of fat and nitrogen absorption in healthy subjects and individuals with cystic fibrosis. J Pediatr Pharmacol Ther. 2007;12(1):47-52doi: 10.5863/1551-6776-12.1.47.
Borowitz, D., Konstan, M. W., O'Rourke, A., Cohen, M., Hendeles, L., & Murray, F. T. (2007). Coefficients of fat and nitrogen absorption in healthy subjects and individuals with cystic fibrosis. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 12(1), 47-52. https://doi.org/10.5863/1551-6776-12.1.47
Borowitz, Drucy, et al. "Coefficients of fat and nitrogen absorption in healthy subjects and individuals with cystic fibrosis." The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG vol. 12,1 (2007): 47-52. doi: https://doi.org/10.5863/1551-6776-12.1.47
Borowitz D, Konstan MW, O'Rourke A, Cohen M, Hendeles L, Murray FT. Coefficients of fat and nitrogen absorption in healthy subjects and individuals with cystic fibrosis. J Pediatr Pharmacol Ther. 2007 Jan;12(1):47-52. doi: 10.5863/1551-6776-12.1.47. PMID: 23055842; PMCID: PMC3462160.
Copy Download .nbib Format: NLM
Reply.

The Journal of pediatrics

Morgan WJ, Pasta DJ, Konstan MW.
PMID: 26873654
J Pediatr. 2016 May;172:228-9. doi: 10.1016/j.jpeds.2016.01.036. Epub 2016 Feb 09.

No abstract available.

Cite
Morgan WJ, Pasta DJ, Konstan MW. Reply. J Pediatr. 2016;172:228-9doi: 10.1016/j.jpeds.2016.01.036.
Morgan, W. J., Pasta, D. J., & Konstan, M. W. (2016). Reply. The Journal of pediatrics, 172228-9. https://doi.org/10.1016/j.jpeds.2016.01.036
Morgan, Wayne J, et al. "Reply." The Journal of pediatrics vol. 172 (2016): 228-9. doi: https://doi.org/10.1016/j.jpeds.2016.01.036
Morgan WJ, Pasta DJ, Konstan MW. Reply. J Pediatr. 2016 May;172:228-9. doi: 10.1016/j.jpeds.2016.01.036. Epub 2016 Feb 09. PMID: 26873654.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 41 entries